A new series of 7,8-disubstituted pyrazolobenzodiazepines based on the lead compound 1 have been synthesized and evaluated for their effects on mitosis and angiogenesis. Described herein is the design, synthesis, SAR, and antitumor activity of these compounds leading to the identification of R1530, which was selected for clinical evaluation.
Keywords: FGFr and PDGFr-β; VGFr-2; antitumor effect; mitosis/angiogenesis inhibitor; pyrazolobenzodiazepines.